Melevodopa/carbidopa explained

Type:	combo
Component1:	Melevodopa
Class1:	Dopamine receptor agonist
Component2:	Carbidopa
Class2:	Aromatic L-amino acid decarboxylase inhibitor
Tradename:	Sirio
Routes Of Administration:	Oral
Synonyms:	Carbidopa/melevodopa; Levodopa methyl ester/carbidopa; CHF-1512; CHF1512; CNP-1512; CNP1512; GT-1512; GT1512; V-1512; V1512

Melevodopa/carbidopa, sold under the brand name Sirio, is a combination of melevodopa, a prodrug of the dopamine precursor and hence non-selective dopamine receptor agonist levodopa (L-DOPA), and carbidopa, a peripherally selective aromatic L-amino acid decarboxylase (AAAD) inhibitor, which is used in the treatment of Parkinson's disease in Italy.^{[1] [2] [3] [4] [5]} It is taken orally in the form of tablets.

See also

• Levodopa/carbidopa
• Foscarbidopa/foslevodopa
• Levodopa/carbidopa/entacapone
• Levodopa/benserazide

Notes and References

1. Web site: Melevodopa/carbidopa . AdisInsight . Springer Nature Switzerland AG . 23 September 2021 . 27 September 2024.
2. Stocchi F, Marconi S . Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio) . Clinical Neuropharmacology . 33 . 4 . 198–203 . July 2010 . 20414107 . 10.1097/WNF.0b013e3181de8924 .
3. Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P . Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease . CNS Drugs . 24 . 2 . 119–129 . February 2010 . 20088619 . 10.2165/11310940-000000000-00000 .
4. Hengartner D, Fernandez HH . The next chapter in symptomatic Parkinson disease treatments . Parkinsonism & Related Disorders . 59 . 39–48 . February 2019 . 30661840 . 10.1016/j.parkreldis.2019.01.002 .
5. Web site: Melevodopa: Uses, Interactions, Mechanism of Action . DrugBank Online . 1 April 2015 . 27 September 2024.